Let’s talk psychedelics and mental health with Christian Angermayer, Florian Brand, and Srinivas Rao
In light of the Covid19 crisis, the need for innovation in mental healthcare has never been more urgent: Antidepressant response rates are unacceptably low, prognosis for addictions is no better than for chronic physical disorders, and anxiolytics come with significant side effects. Conversely, psychedelic medicine promises to bridge the gap between what the mental healthcare system can provide and what people really need.
Join Christian Angermayer, serial entrepreneur and founder of ATAI Life Sciences, for a deep dive into the future of mental healthcare with Florian Brand, CEO and Srinivas Rao, Chief Scientific Officer of ATAI Life Sciences. You’ll learn about the latest in psychedelic research and investment, how artificial intelligence is helping drive next generation drug discovery – and most importantly – how the patient experience will be transformed by these incredible medicines.
Please join us in creating a healthier and happier world – for everyone.